The disclosure follows the diagnostic. On June 9, 2026, GM Global Technology Operations was granted US12651810B2, "Electrochemical devices with multifunctional electrode separator assemblies having built-in reference electrodes." The CPC codes span battery separators and housings (H01M 50/54, 50/46, 50/533/534/536, 50/249) and EV power (B60L 50/64). A reference electrode is a diagnostic instrument inside the cell: it gives a stable voltage baseline against which the health of the electrodes can be measured precisely.
Why does this matter on a desk that tracks material-event filings? Because the chain from battery problem to public disclosure runs through detection. A defect you catch in validation is an engineering note; a defect you catch in the field after a thermal event is an 8-K and a NHTSA filing. In-cell diagnostics like a built-in reference electrode push detection earlier in that chain — and earlier detection generally means a smaller, more controlled disclosure rather than a large surprise reserve.
A recall is a reserve before it's a headline. The financial expression of better diagnostics is a warranty accrual that's set more accurately and earlier, and fewer of the abrupt, large 8-K recall disclosures that move a stock. GM, like every EV-scaling automaker, carries battery warranty exposure; investing in diagnostic IP is investing in keeping that exposure measured rather than explosive.
Scope discipline applies here too: the grant covers the specific separator-plus-reference-electrode construction in its claims, not diagnostics broadly. Reference electrodes are known in battery science; the protectable novelty is the integration GM claims. For a risk reader, the point isn't the claim breadth — it's that GM is building measurement into the cell, and measurement is what stands between a degradation trend and a disclosure event.
The receipts live in the filings: warranty reserve movements in the 10-K/10-Q and any recall language in 8-Ks, all surfaceable through the SEC filing evidence index. This patent is the upstream diagnostic; the filings are the downstream disclosure. Reading them together is how you tell whether better diagnostics are actually shrinking the reserve.